[go: up one dir, main page]

AR008638A1 - Utilizacion de un inhibidor de la actividad del acido retinoico en una composicion cosmetica o para la preparacion de una composicion farmaceutica - Google Patents

Utilizacion de un inhibidor de la actividad del acido retinoico en una composicion cosmetica o para la preparacion de una composicion farmaceutica

Info

Publication number
AR008638A1
AR008638A1 ARP970104308A ARP970104308A AR008638A1 AR 008638 A1 AR008638 A1 AR 008638A1 AR P970104308 A ARP970104308 A AR P970104308A AR P970104308 A ARP970104308 A AR P970104308A AR 008638 A1 AR008638 A1 AR 008638A1
Authority
AR
Argentina
Prior art keywords
acid
benzoic
benzoic acid
tetrahydro
tetramethyl
Prior art date
Application number
ARP970104308A
Other languages
English (en)
Original Assignee
Galderma Ct Internat De Rech S Dermatologiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Ct Internat De Rech S Dermatologiques filed Critical Galderma Ct Internat De Rech S Dermatologiques
Publication of AR008638A1 publication Critical patent/AR008638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Cosmetics (AREA)
  • Cultivation Receptacles Or Flower-Pots, Or Pots For Seedlings (AREA)

Abstract

Utilizacion de un inhibidor de la actividad del ácido retinoico en una composicion cosmética o para la preparacion de una composicion farmacéutica,caracterizada porque el inhibidor de la actividad del ácido retinoico o la composicion farmacéutica están destinados a favorecer la cicatrizacion, enparticular la cicatrizacion cutánea. El inhibidor de la actividad del ácido retinoico puede ser un antagonista del ácido retinoico que preferentemente seselecciona entre los siguientes compuestos: -ácido 4-[7-(1-adamantil)-6- metoxietoximetoxi-2-naftil]benzoico, -ácido 4-{[5,6-dihidro-5,5-dimetil-8-(4-metilfenil)-2-naftalenil]etinil}benxoico, -ácido(E)-4-[2-(4,4-dimetil-7- -heptiloxi-1,1-dioxo-3,4-dihidro-2H-1-benzotiopiran--6-il)propenil]benzoico, --ácido 4-[4,5,7,8,9,10-hexahidro-7,7,10,10-tetrametil-1-(3-piridilmetil)an-tra[ 1,2--b]pirrol-3-il]benzoico, -ácido 4-[4,5,7,8,9,10-hexahidro-7,7,10,10-tetrametil-1-(3-piridilmetil)tio-antra[1,2--b]pirrol--3-il]benzoico, -ácido 4- [4,5,7,8,9,10-hexahidro-7,7,10,10,-tetrametil-1-(3-piridilmetil)antra[1,2--d]pirazol-3-il]benzoico, -ácido 4-[3-(diamantil)-4-metoxibenzamido]benzoico, -ácido 4-[3-(diamantil)-4-metoxibenzoiloxi]benzoico, -ácido 4-(N-fenil-5,6,7,8-tetrahidro 5,5,8,8-tetrametilnafto [2,3-d]imidazol-2-il)benzoico, -ácido 4- (N- bencil-5,6,7,8-tetrahidro-5,5,8,8-tetrametilnafto[2,3-d]imidazol-2-il)benzoico,-ácido 4-(5H-7,8,9,10-tetrahidro-5,7,7,10,10-pentametilbenceno[c]-nafto[2,3--b] [1,4]diazepin-3-il)benzoico, -ácido4-[1-(1-metoxi-2,2,2-trifluoroetil)-5,6,7,8-tetrahidro-5,5,8,8-tetrametil-3--antracenil]benzoico, ácido 4-(5,5-dimetil-8- fenil-5,6-dihidro-naftalen-2-iletinil)benzoico, -ácido 4-(5,5-dimetil-8-p-tolil-5,6-dihidro-naftalen-2-iletinil)benzoico.
ARP970104308A 1996-09-20 1997-09-19 Utilizacion de un inhibidor de la actividad del acido retinoico en una composicion cosmetica o para la preparacion de una composicion farmaceutica AR008638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9611511A FR2753627B1 (fr) 1996-09-20 1996-09-20 Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation

Publications (1)

Publication Number Publication Date
AR008638A1 true AR008638A1 (es) 2000-02-09

Family

ID=9495934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104308A AR008638A1 (es) 1996-09-20 1997-09-19 Utilizacion de un inhibidor de la actividad del acido retinoico en una composicion cosmetica o para la preparacion de una composicion farmaceutica

Country Status (14)

Country Link
US (1) US5973007A (es)
EP (1) EP0874626B1 (es)
JP (1) JPH11500464A (es)
AR (1) AR008638A1 (es)
AT (1) ATE285761T1 (es)
AU (1) AU707390B2 (es)
BR (1) BR9709154A (es)
CA (1) CA2236309A1 (es)
DE (1) DE69732092D1 (es)
FR (1) FR2753627B1 (es)
MX (1) MX9803995A (es)
NZ (1) NZ330401A (es)
WO (1) WO1998011886A1 (es)
ZA (1) ZA978400B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
FR2847167A1 (fr) * 2002-11-15 2004-05-21 Galderma Res & Dev UTILISATION D'UN ANTAGONISTE DES RECEPTEURS RARs POUR POTENTIALISER L'ACTION DU TGFb
WO2004045595A1 (en) * 2002-11-15 2004-06-03 Galderma Research & Development, S.N.C. USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ
US20070299041A1 (en) * 2004-05-26 2007-12-27 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
US20070049579A1 (en) * 2005-03-04 2007-03-01 Ryozo Nagai Medicament having neovascularization promoting action
EP1764411B1 (en) 2005-07-26 2013-10-02 Kao Corporation Alkaline xylanase
US20080027031A1 (en) * 2006-03-08 2008-01-31 Kinemed, Inc. Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2931661B1 (fr) 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide.
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
JP7534962B2 (ja) 2018-06-19 2024-08-15 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237003A (en) * 1990-02-12 1992-12-23 Squibb & Sons Inc A bandage comprising a retinoid in or on the skin contacting surface
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
FI943948L (fi) * 1992-12-28 1994-08-26 Eisai Co Ltd Heterosykliset hiilihappojohdannaiset
FR2713640B1 (fr) * 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
CA2138000A1 (en) * 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
FR2735371B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity

Also Published As

Publication number Publication date
FR2753627B1 (fr) 2003-02-21
AU707390B2 (en) 1999-07-08
ZA978400B (en) 1998-03-26
AU4306197A (en) 1998-04-14
EP0874626B1 (fr) 2004-12-29
EP0874626A1 (fr) 1998-11-04
FR2753627A1 (fr) 1998-03-27
JPH11500464A (ja) 1999-01-12
CA2236309A1 (fr) 1998-03-26
NZ330401A (en) 1999-05-28
DE69732092D1 (de) 2005-02-03
BR9709154A (pt) 1999-08-03
WO1998011886A1 (fr) 1998-03-26
ATE285761T1 (de) 2005-01-15
MX9803995A (es) 1998-09-30
US5973007A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
AR008638A1 (es) Utilizacion de un inhibidor de la actividad del acido retinoico en una composicion cosmetica o para la preparacion de una composicion farmaceutica
UY24816A1 (es) Sulfonamidas agonistas de prostaglandinas para la prevención y restauración de la masa ósea
AR009398A1 (es) Utilizacion de inhibidores de la actividad del acido retinoico para el tratamiento de pieles sensibles y/o los danos agudos inducidos por los rayos u.v.
ITMI951223A1 (it) Forma farmaceutica solida ad uso orale
ES2084944T3 (es) Amidas terapeuticas.
PA8569201A1 (es) "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
ES2138648T3 (es) Derivados de 1h-indol-3-acetamidas como inhibidores de spla2.
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
FI951614A0 (fi) D-vitamiinisarjan 25-karboksyylihappojohdannaisia, menetelmät niiden valmistamiseksi, näissä menetelmissä käytettävät välituotteet, näitä johdansia sisältävät farmaseuttiset valmisteet ja näiden johdannaisten käyttö lääkeaineiden valmistukseen
UY26253A1 (es) Derivados del triazol y del imidazol
GB2193961A (en) 3-hydroxybenzo(b)thiophene-2-carboxamides
CA2309304A1 (fr) Agnim comme agents anti-inflammatoires dans les tissus superficiels des mammiferes
CA2258513A1 (en) Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT1233953E (pt) Novos derivados de benzotiadiazinas processo para a sua preparacao e as composicoes farmaceuticas que os contem
Soliven et al. Arachidonic acid and its metabolites increase Cai in cultured rat oligodendrocytes
Hartman et al. Comparison of antiinflammatory and antiallergic drugs in the melittin-and D49 PLA2-induced mouse paw edema models
PE20050393A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion
KR20010043147A (ko) 멜라닌 생성을 촉진하는 화합물의 확인을 위한 분석법 및그 분석법에 의해 확인되는 레티노이드류 화합물
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
ITRM930286A1 (it) Composizione farmaceutica per somministrazione rettale nel trattamento di cefalea e relativo metodo di preparazione ed impiego.
ES2153457T3 (es) Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2190574T3 (es) Nuevos compuestos del indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US5827500A (en) Process for identifying RAR-receptor-antagonist compounds
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal